The site offers API process development and manufacturing from preclinical to commercial manufacturing. The 74-acre campus includes 15 plants, including plants for HPAPI, flow chemistry and spray dried dispersion. The total reactor volume exceeds 1,800 m³.
We have recently opened our new R&D Center in Changzhou, significantly expanding our capabilities in developing advanced therapies covering small molecules, oligonucleotides, and peptides as well as complex synthetic conjugates. Strategically located just 15 minutes from our existing Changzhou API manufacturing site, the R&D Center is designed with six R&D buildings. Upon full operation, the Center will accommodate approximately 3,000+ scientists with 170+ specialized laboratories. The first operational building, dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates, spans over 160,000 square feet. The modular lab integrates essential workflows with latest digitalization and automation controls to achieve faster data turnaround and higher efficiency.
It supports various API enabling technologies such as crystallization and particle engineering, biocatalysis, continuous manufacturing (flow chemistry), chemo-catalysis, and prep-HPLC & SFC & SMB.
Our Changzhou site has successfully passed numerous inspections by the US FDA, China NMPA, Japan PMDA, South Korea MFDS, and Brazil ANVISA.
